Print


BioRunUp has evolved into an informed Biotech trading community seeking to generate consistent profits (in any market condition) through a variety of long, short and options based strategies.


Take a look at our recent verified profits of over $500,000
Mark Messier
Mike Havrilla

Join Our FREE Mailing List and Receive the eBook
"Five Tips to Better Biotech Trading / 
Understanding the BioCatalyst Process"
Some of the features of the new BioRunUp.com include:

- Detailed Reports on Upcoming FDA and Clinical Trial Trades
- REAL TIME Posting of Trades (Entries and Exits)
- Clinical and Regualtory Catalyst Database with over 300 events and updated daily 
- Members Only Live Interactive Webinars 
- Live Chat Room 
- Video Lessons / Trade Reviews
- Chart / Technical Analysis 
- BioRunUp Forums
- Run-Up Valuation Studies
- Weekly Watchlist Newsletter
- Email / SMS (Text Message) Alerts of critical news
- Screenshots of BioRunUp (Mark Messier) and Mike Havrilla's Trading Accounts
- A More Detailed FDA Calendar
- Historical FDA Tracker
- Bio-Pharma, FDA, Clinical Trials, and Stock Market News Updates
- Direct Email Communication
- Affiliate Program

The cost for an annual subscription is $497 and includes all the above features. We also offer a monthly plan for $79.95. 


Take a look at excerpts from BioRunUp subscriber testimonials:

"My most recent and profitable trade are the EXAS Oct $5 options which I purchased at $.40 off of BioRunUp blog alert. They are currently yielding a 700% return!!!"

"Within 1 month my brand new porfolio was up over 23%!"

"I started the biorunup method on Aug. 9th 2010 and before the end of Sept. I was up 35%."

"In the first month I made a 13% return, doubling the return of the market as a whole - without leverage. To date, I have never failed to beat the market when applying the methods outlined in the pages of BioRunUp."

"
I don’t ever take recommendations from people on the Internet, but this one looked right, felt right and sounded right.  Thanks BioRunUp, you made me a fortune."

 

Recent articles

  This Week's Watchlist 2/21/12 (in: Articles)
  $CORT / $CHTP Video Trading Gameplan (in: Articles)
  New Diabetes Drug Delivery Trade for Mike and Mark (in: Articles)
  $FRX Late-Stage Pipeline Is Key as Lexapro Patent Cliff Looms (in: Articles)
  $HZNP FDA Decision for Lodotra Is a Trading Catalyst on the Horizon this Summer (in: Articles)
  This Week's Catalyst Updates 2/12/12 (in: Articles)
  This Week's Watchlist 2/13/12 (in: Articles)
  New Medical Device Trade for Mike (in: Articles)
  New Phase 3 Catalyst Trade for Mike with Strong Balance Sheet (in: Articles)
  $ECTE Symphony Glucose Monitoring System is Key Valuation Catalyst (in: Articles)
  BioRunUp Webinar Notice (in: Articles)
  $EXAS Key Data for Colon Cancer Screening Test Expected Around 3Q12 (in: Articles)
  2/6/12 Watchlist and Clinical Database Summary (in: Articles)
  Trading Options around $CORT 2/17/12 (in: Articles)
  $ANAC Expects to Report Initial Phase 3 Data in Late 2012 (in: Articles)
  Hepatitis C Drug Delivery Stock Trade for Mike (in: Articles)
  $ONTY Stock Chart Analysis (in: Articles)
  $DSCO Run-Up Valuation Study (in: Articles)
  $RMTI Dialysis Product Specialist Awaits Key SFP Clinical Trial Results (in: Articles)
  This Week's Catalyst Calendar Summary - 1/29/12 (in: Articles)